Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Black Diamond Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. MOU, LIYUAN is the busiest examiner, managing 1 busiest examiner pending action. This 1 busiest examiner pending action constitutes the company's total 1 pending office action. The focus on 1 distinct art unit indicates a specific biological or pharmaceutical invention is currently being evaluated by the USPTO.
Because there is only 1 pending office action, the company's immediate patent strategy is concentrated on a single point of contact within the USPTO. This lack of diversification in examiners or art units means that the company's current patent prospects are tied to the evaluation of MOU, LIYUAN within that 1 distinct art unit. Practitioners should focus on the specific preferences and history of this 1 distinct examiner. The alignment of 1 distinct examiner and 1 distinct art unit suggests a narrow and specific focus in the company's current biotech filings. This 1 pending office action is the only one currently being evaluated for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689967 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18689967 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial